BigHat Biosciences designs safer, more effective antibody therapies for patients using machine learning and synthetic biology.
BigHat Biosciences designs safer, more effective antibody therapies for patients using machine learning and synthetic biology.
We apply these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.
BigHat’s Milliner platform integrates a synthetic biology-based high-speed wet lab with state-of-the-art machine learning technologies into a full-stack antibody discovery and engineering platform.
Hundreds of recombinant antibodies can be synthesized, purified, and fully characterized for biophysics and function in a single, weekly workcell.
Antibodies are some of the most powerful and successful medicines for diseases from infections to cancers. Next-generation therapies promise greater safety and efficacy for patients with rational molecular design.
We’re a Series B biotech outside San Francisco with a pipeline of wholly-owned and partnered therapeutic programs. We’ve raised >$100M from top investors to pursue our vision to create safer, more effective antibody therapies for patients using machine learning and synthetic biology.
Learn more about BigHat
BigHat engages with strategic partners to tackle complex protein therapeutic design challenges.
Find out more